Prospective study of cancer in Japanese patients with type 2 diabetes: the Fukuoka Diabetes Registry.
Cancer
Cohort study
Isoflavone
Type 2 diabetes
Journal
Diabetology international
ISSN: 2190-1678
Titre abrégé: Diabetol Int
Pays: Japan
ID NLM: 101553224
Informations de publication
Date de publication:
Oct 2019
Oct 2019
Historique:
received:
05
11
2018
accepted:
13
02
2019
entrez:
9
10
2019
pubmed:
9
10
2019
medline:
9
10
2019
Statut:
epublish
Résumé
Although the association between type 2 diabetes and cancer has been reported, few epidemiological studies have been conducted in Japanese patients whose leading cause of death is cancer. We prospectively studied the incidence of site-specific cancer, risk factors for developing cancer, cancer death, and survival in Japanese patients with type 2 diabetes. We followed 4923 participants (mean age, 65 years) with type 2 diabetes attending an outpatient diabetes clinic for a median of 5.3 years (follow-up rate, 99.0%). During the follow-up period, cancer occurred in 450 participants (incidence rate, 22.3/1000 person-years in men and 12.2/1000 person-years in women). In men, prostate cancer was the most common cancer (4.3/1000 person-years), colorectal cancer was the second (3.6/1000 person-years), and gastric cancer was the third (3.3/1000 person-years). In women, colorectal cancer was the most common cancer (2.6/1000 person-years), gastric cancer was the second (2.0/1000 person-years), and breast cancer was the third (1.4/1000 person-years). Smoking, male sex, low-density lipoprotein cholesterol, family history of cancer, and reduced intake of isoflavone daidzein were significant risk factors for developing cancer using multivariable Cox proportional hazards models. The leading cancer death was lung cancer in men and pancreatic cancer in women. The survival was the best for prostate cancer and the worst for pancreatic cancer (2-year cancer-specific survival 95.4%, 30.0%, respectively). Since the leading cause of death in patients with type 2 diabetes is cancer in Japan, clinicians should be aware of epidemiological data regarding cancer besides diabetic complications.
Sections du résumé
BACKGROUND
BACKGROUND
Although the association between type 2 diabetes and cancer has been reported, few epidemiological studies have been conducted in Japanese patients whose leading cause of death is cancer. We prospectively studied the incidence of site-specific cancer, risk factors for developing cancer, cancer death, and survival in Japanese patients with type 2 diabetes.
METHODS
METHODS
We followed 4923 participants (mean age, 65 years) with type 2 diabetes attending an outpatient diabetes clinic for a median of 5.3 years (follow-up rate, 99.0%).
RESULTS
RESULTS
During the follow-up period, cancer occurred in 450 participants (incidence rate, 22.3/1000 person-years in men and 12.2/1000 person-years in women). In men, prostate cancer was the most common cancer (4.3/1000 person-years), colorectal cancer was the second (3.6/1000 person-years), and gastric cancer was the third (3.3/1000 person-years). In women, colorectal cancer was the most common cancer (2.6/1000 person-years), gastric cancer was the second (2.0/1000 person-years), and breast cancer was the third (1.4/1000 person-years). Smoking, male sex, low-density lipoprotein cholesterol, family history of cancer, and reduced intake of isoflavone daidzein were significant risk factors for developing cancer using multivariable Cox proportional hazards models. The leading cancer death was lung cancer in men and pancreatic cancer in women. The survival was the best for prostate cancer and the worst for pancreatic cancer (2-year cancer-specific survival 95.4%, 30.0%, respectively).
CONCLUSIONS
CONCLUSIONS
Since the leading cause of death in patients with type 2 diabetes is cancer in Japan, clinicians should be aware of epidemiological data regarding cancer besides diabetic complications.
Identifiants
pubmed: 31592402
doi: 10.1007/s13340-019-00390-0
pii: 390
pmc: PMC6763543
doi:
Types de publication
Journal Article
Langues
eng
Pagination
260-267Informations de copyright
© The Japan Diabetes Society 2019.
Déclaration de conflit d'intérêts
Conflict of interestThe authors declare that there is no conflict of interest associated with this manuscript.
Références
Diabetol Int. 2015 Aug 25;7(2):167-172
pubmed: 30603260
Int J Cancer. 2015 Aug 15;137(4):885-92
pubmed: 25639758
J Epidemiol. 2012;22(2):151-9
pubmed: 22343326
Br J Cancer. 2004 Jan 12;90(1):128-34
pubmed: 14710219
Med Sci Sports Exerc. 2000 Sep;32(9 Suppl):S498-504
pubmed: 10993420
Asian Pac J Cancer Prev. 2012;13(8):4097-100
pubmed: 23098523
Jpn J Clin Oncol. 2015 Sep;45(9):884-91
pubmed: 26142437
Lancet Diabetes Endocrinol. 2018 Feb;6(2):95-104
pubmed: 29195904
Diabetes Res Clin Pract. 2013 Mar;99(3):241-9
pubmed: 23298664
BMC Cancer. 2016 Oct 10;16(1):785
pubmed: 27724912
Cancer Res. 2016 Apr 15;76(8):2063-70
pubmed: 27197250
Oncotarget. 2017 Aug 4;8(37):62478-62488
pubmed: 28977962
Springerplus. 2016 Sep 13;5(1):1548
pubmed: 27652121
Am J Epidemiol. 2008 Aug 15;168(4):391-403
pubmed: 18599492
Cancer. 2017 Jun 1;123(11):2070-2079
pubmed: 28263368
Ann Oncol. 2012 May;23(5):1362-9
pubmed: 22048150
J Diabetes Investig. 2013 May 6;4(3):225-32
pubmed: 24843658
Cancer Sci. 2016 Apr;107(4):521-7
pubmed: 27079439
Cancer Sci. 2013 Nov;104(11):1499-507
pubmed: 23889822
Arch Intern Med. 2006 Sep 25;166(17):1871-7
pubmed: 17000944
Br J Cancer. 2005 Jan 17;92(1):182-7
pubmed: 15597102
Int J Cancer. 2005 Jan 1;113(1):148-57
pubmed: 15386435
Cancer Causes Control. 2004 Sep;15(7):671-80
pubmed: 15280625
Nutrients. 2018 Jan 04;10(1):null
pubmed: 29300347
Cancer Sci. 2013 Jan;104(1):9-14
pubmed: 23066889
Eur Urol. 2012 Jun;61(6):1079-92
pubmed: 22424666
Diabetol Int. 2017 Mar 28;8(2):117-136
pubmed: 30603315
Diabetol Int. 2016 Mar 7;7(1):12-15
pubmed: 30603237
Sci Rep. 2016 May 12;6:25939
pubmed: 27170217
Int J Cancer. 2009 Dec 1;125(11):2679-86
pubmed: 19544528
Diabetes Care. 2013 Mar;36(3):611-7
pubmed: 23150286
J Epidemiol. 2011;21(1):67-74
pubmed: 21160131
Jpn J Clin Oncol. 2005 Jul;35(7):404-11
pubmed: 15987784